

UChicago Medicine Presentations at the 2019 ASH Annual Meeting

Start Time	End Time	Session No./Title	Presentation Title	Paper No.	Location	Speaker	Other UChicago authors
Scientific Workshops – Friday, December 6, 2019							
12:30 PM	4:30 PM	Friday Satellite Symposia	New Data and Paradigms in ALL: Insights and Applications		Plaza International I-K (Hyatt Regency Orlando)	Wendy Stock, MD	
1:30 PM 2:30 PM 3:30 PM	2:00 PM 3:00 PM 4:00 PM	ASH-a-Palooza Program: Trainee Activities and Services	Blood Buddies: Adult & Pediatric Clinical Non-Malignant Hem		Bays 208-214 (Topgolf Orlando)	Jill de Jong, MD, PhD	
1:30 PM 2:30 PM 3:30 PM	2:00 PM 3:00 PM 4:00 PM	ASH-a-Palooza Program: Trainee Activities and Services	Blood Buddies: BMT Peds and Adult		Bays 221-227 (Topgolf Orlando)	James LaBelle, MD, PhD	
2:30 PM	3:30 PM	Friday Scientific Workshops/Panel Discussion	Frequency of Causative Germline Genetic Variants in Young Adults with Myelodysplastic Syndrome or Aplastic Anemia Irrespective of Family History		Tangerine 1 (WF1), Level 2 (Orange County Convention Center)	Simone Feurstein, MD	
2:30 PM 2:45 PM	2:35 PM 2:50 PM	ASH-a-Palooza Program: Trainee Activities and Services	Blood Drop: Vascular Anomalies- Not everything is an AVM		Bays 124-129 (Topgolf Orlando)	Radhika Peddinti, MD	
2:40 PM	3:30 PM	Friday Scientific Workshops	CUX1 Deficiency Potentiates Ras Signaling to Drive High-Risk Myeloid Malignancy		Tangerine 1 (WF1), Level 2 (Orange County Convention Center)	Megan E. McNerney, MD, PhD	

UChicago Medicine Presentations at the 2019 ASH Annual Meeting

4:30 PM	5:15 PM	Friday Scientific Workshops/Panel Discussion	Molecular Profiling in Patients with Germline Predisposition Syndromes: When to Act, When to Watch		Tangerine 1 (WF1), Level 2 (Orange County Convention Center)	Michael W. Drazer, MD	
5:15 PM	5:55 PM	Friday Scientific Workshops	Heterozygous CSF3R Mutations: A Possible New Germline Predisposition Syndrome		Tangerine 1 (WF1), Level 2 (Orange County Convention Center)	Amy M Trottier, MSc, MD, FRCPC	
5:55 PM	6:00 PM	Friday Scientific Workshops	Closing Remarks		Tangerine 1 (WF1), Level 2 (Orange County Convention Center)	Lucy A. Godley, MD, PhD	
ASH Annual Meeting – Saturday, December 7, 2019							
9:30 AM	11:00 AM	615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction and Post-Remission Therapy	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study	E2906	W304 (Orange County Convention Center)	James M. Foran, MD	Daniel A. Arber, MD
10:45 AM	11:00 AM	602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Epigenetic Alteration	Deficiency of CUX1, Encoded on 7q, Blocks the Normal HSC DNA Damage Response and Drives Highly Penetrant Therapy-Related Myeloid Neoplasms in Mice	109	Sunburst Room (W340)	Megan E. McNerney, MD, PhD	Stephen J. Kron, MD, PhD; Sandeep Gurbuxani, MBBS, PhD

UChicago Medicine Presentations at the 2019 ASH Annual Meeting

11:15 AM	12:15 PM	Career Development Lunch	Adult Clinical Malignant Hematology		Orlando Ballroom MN (Hyatt Regency Orlando)	Wendy Stock, MD	
11:15 AM	12:15 PM	Career Development Lunch	Pediatric Clinical Malignant Hematology		Orlando Ballroom MN (Hyatt Regency Orlando)	Tara O. Henderson, MD, MPH	
5:30 PM	7:30 PM	704. Immunotherapies: Poster I	Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation	1956	Hall B, Level 2	Amy Wang, MD, MPH	Justin Kline, MD; Wendy Stock, MD; Richard A. Larson, MD; Peter A. Riedell, MD; Michael R. Bishop, MD and Hongtao Liu, MD, PhD
5:30 PM	7:30 PM	653. Myeloma: Therapy, excluding Transplantation: Poster I	Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)	1876	Hall B, Level 2	Ajai Chari, MD	Andrzej Jakubowiak, MD, PhD
5:30 PM	7:30 PM	653. Myeloma: Therapy, excluding Transplantation: Poster I	Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies	1891	Hall B, Level 2	Ola Landgren, MD, PhD	Andrzej Jakubowiak, MD, PhD; Jagoda K. Jasielec, MD
5:30 PM	7:30 PM	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observ	A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas	1599	Hall B, Level 2	Peter A. Riedell, MD	Michael R. Bishop, MD

UChicago Medicine Presentations at the 2019 ASH Annual Meeting

		ational Studies: Poster I					
5:30 PM	7:30 PM	653. Myeloma: Therapy, excluding Transplantation: Poster I	Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy	1854	Hall B, Level 2	Ajai Chari, MD	Andrzej Jakubowiak, MD, PhD; Jagoda K. Jasielec, MD
5:30 PM	7:30 PM	653. Myeloma: Therapy, excluding Transplantation: Poster I	Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)–CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	1869	Hall B, Level 2	Noopur S. Raje, MD	Andrzej Jakubowiak, MD, PhD
Sunday, December 8, 2019							
7:30 AM	9:00 AM	Stromal Cell Immune Regulation in the Microenvironment	Lymphatic Control of the Tumor Immune Microenvironment	SCI-46	Tangerine 1 (WF1), Level 2	Melody A. Swartz, PhD	
9:30 AM	9:45 AM	625. Lymphoma: Pre- Clinical— Chemotherapy and Biologic Agents: Immune Signaling and Immunotherapy in Lymphoma	Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL	391	Tangerine 2 (WF2), Level 2	Nicole Sunseri, MD, PhD	Justin Kline, MD; Sonali M. Smith, MD
11:15 AM	12:15 AM	Special-Interest Session	Featured Topic: Taking a bite out of CAR T Cells		Hall E1, Level 2		Wendy Stock, MD
11:15 AM	12:15 PM	Trainee Didactic Session 2: Application of Microarray and Large Datasets to	Application of Microarray and Large Datasets to Hematology and Bioinformatics		W315, Level 3	Lucy A. Godley, MD, PhD	

UChicago Medicine Presentations at the 2019 ASH Annual Meeting

		Hematology and Bioinformatics					
12:00 PM	12:15 PM	641. CLL: Biology and Pathophysiology, excluding Therapy: Mechanisms of Response and Resistance to Targeted Agents	Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication	475	W414AB, Level 4	Richard A. Larson, MD	
4:30 PM	6:00 PM	Stromal Cell Immune Regulation in the Microenvironment	Lymphatic Control of the Tumor Immune Microenvironment	SCI-46	W230, Level 2	Melody A. Swartz, PhD	
6:00 PM	8:00 PM	603. Oncogenes and Tumor Suppressors: Poster II	New Germline Syndrome Discovery: Heterozygous CSF3R Mutations May Predispose to Myeloid and Lymphoid Malignancies	2543	Hall B, Level 2	Lucy A. Godley, MD, PhD	
6:00 PM	8:00 PM	732. Clinical Allogeneic Transplantation: Results: Poster II	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS	3324	Hall B, Level 2	Satyajit Kosuri, MD	Hongtao Liu, MD, PhD; Lucy A Godley, MD, PhD; Richard A. Larson, MD; Olatoyosi Odenike, MD; Wendy Stock, MD; Justin Kline, MD; Peter A. Riedell, MD; Michael R. Bishop, MD
Monday, December 9, 2019							
7:00 AM	8:30 AM	653. Myeloma: Therapy, excluding Transplantation:	Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against	577	Hall D, Level 2	Deepu Madduri, MD	Andrzej Jakubowiak, MD, PhD

UChicago Medicine Presentations at the 2019 ASH Annual Meeting

		Novelty in CAR T in Relapsed/Refractory Multiple Myeloma	B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)				
10:30 AM	12:00 PM	653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update	691	Hall E1, Level 2	Peter M. Voorhees, MD	Andrzej Jakubowiak, MD, PhD
4:30 PM	6:00 PM	653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone	859	Hall E2, Level 2	Maria-Victoria Mateos	Andrzej Jakubowiak, MD, PhD
6:00 PM	7:00 PM	634. Myeloproliferative Syndromes: Clinical: Poster III	Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors	4176	Hall B, Level 2	Anand Ashwin Patel, MD	Hongtao Liu, MD, PhD; Sandeep Gurbuxani, MBBS, PhD; Michael Thirman, MD; Richard A. Larson, MD; Wendy Stock, MD; Jeremy Segal, MD, PhD; and Olatoyosi Odenike, MD
6:00 PM	8:00 PM	901. Health Services Research—Non-	A Pilot Study of a Functional Pain Assessment for Adult Patients Admitted with Sickle Cell Pain Crisis	4693	Hall B, Level 2	Marquita Nelson, MD	Kenneth Cohen, MD

UChicago Medicine Presentations at the 2019 ASH Annual Meeting

		Malignant Conditions: Poster III					
6:15 PM	7:45 PM	653. Myeloma: Therapy, excluding Transplantation: Novel Therapy for Relapsed Myeloma	Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA- targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset	928	Valencia A (W415A) (Orange County Convention Center)	Enrique Zudaire, PhD	Andrzej Jakubowiak, MD, PhD
7:30 PM	7:45 PM	621. Lymphoma— Genetic/Epigenetic Biology: DLBCL Genomics and Molecular Signatures	Integrative Immunogenomic Characterization of Diffuse Large B- Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes	924	W414AB, Level 4	Michael Leukam, MD, MS	Sonali M. Smith, MD; Justin Kline, MD
Tuesday, December 10, 2019							
9:30 AM	9:45 AM	General Sessions	Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medal		Hall D, Level 2	Richard A. Larson, MD (honoree, not lecturing)	